Canvuparatide (MBX 2109)

May 07, 2026 — MBX Biosciences, Inc. (Nasdaq: MBX) reported first-quarter 2026 financial results and pipeline updates for its endocrine/metabolic peptide programs. The company said results from the 12-week Phase 2 Avail™ trial of once-weekly canvuparatide for chronic hypoparathyroidism were accepted for an oral presentation at ENDO 2026 (June 13, 2026), with one-year open-label extension data to be presented at the Parathyroid Summit (June 12, 2026). Following a successful FDA End-of-Phase 2 meeting, MBX remains on track to initiate a Phase 3 confirmatory canvuparatide trial in Q3 2026.

MBX will host an “Obesity Day” investor event on May 11, 2026 featuring initial blinded Phase 1 data for MBX 4291; 12-week multiple ascending dose Phase 1 data are expected in Q4 2026. Additional obesity candidates planned include an amycretin prodrug (Q2 2026) and a GLP-1/GIP/GCGR triple-agonist prodrug (Q3 2026). Phase 2a STEADI™ results for imapextide in post-bariatric hypoglycemia are expected in Q2 2026.

Financially, MBX reported $440.0M in cash/investments (runway into 2029), Q1 R&D expense of $18.5M (vs $22.4M in Q1 2025), G&A of $8.8M (vs $4.1M), and net loss of $23.5M (vs $23.9M). The company also appointed Mark Soued as Chief Commercial Officer.